



PB 124 of 2025

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 10)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 98C(1) of the *National Health Act 1953*.

Dated 29 October 2025

REBECCA RICHARDSON

Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division

Contents

1.	Name.....	1
2.	Commencement.....	1
3.	Authority.....	1
4.	Schedules.....	1
	Schedule 1—Amendments.....	2
	<i>National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)</i>	<i>2</i>

1. Name

- (1) This instrument is the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 10)*.
- (2) This instrument may also be cited as PB 124 of 2025.

2. Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 November 2025	1 November 2025

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3. Authority

This instrument is made under subsection 98C(1) of the *National Health Act 1953*.

4. Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

- [1] **Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 10 mg (modified release) (s19A)**

insert:

Methylphenidate	Capsule containing methylphenidate hydrochloride 10 mg (modified release) (Switzerland) (S19A)
-----------------	--

- [2] **Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 20 mg (modified release) (s19A)**

insert:

Methylphenidate	Capsule containing methylphenidate hydrochloride 20 mg (modified release) (Switzerland) (s19A)
-----------------	--

- [3] **Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 30 mg (modified release) (s19A)**

insert:

Methylphenidate	Capsule containing methylphenidate hydrochloride 30 mg (modified release) Ritalin LA (Switzerland) (s19A)
Methylphenidate	Capsule containing methylphenidate hydrochloride 30 mg (modified release) (Switzerland) (s19A)

- [4] **Schedule 3, after entry for Methylphenidate in the form Capsule containing methylphenidate hydrochloride 40 mg (modified release)**

insert:

Methylphenidate	Capsule containing methylphenidate hydrochloride 40 mg (modified release) (Switzerland) (s19A)
-----------------	--

- [5] **Schedule 4, omit entry for Betaxolol**

- [6] **Schedule 4, entries for Estradiol with norethisterone**

(a) *omit:*

Estradiol with norethisterone	Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)
-------------------------------	---

(b) *omit:*

Estradiol with norethisterone	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)
-------------------------------	---